CTY · NASDAQ · Healthcare · $1.0B
$20.71-6.5%vs prev closeclose of 2026-10-30 · not real-time
Some axes lack data (–)
A summary of valuation factors — not a buy recommendation. You decide.
| Company | PER | PBR | ROE | Div | Score |
|---|---|---|---|---|---|
| City Therapeutics Inc. | – | – | – | 0.0% | – |
| HealthStream Inc. | 46.8 | 2.8 | 6% | 0.4% | 50 |
| Integra LifeSciences Holdings Corporation | 75.0 | 0.9 | 1% | 0.0% | 58 |
| Lumexa Imaging Holdings Inc. | – | 1.8 | – | 0.0% | 34 |
| iRadimed Corporation | 42.8 | 10.4 | 24% | 0.9% | 49 |
| Rigel Pharmaceuticals Inc. | 3.0 | 2.2 | 127% | 0.0% | 55 |
Same sector, nearest by market cap · – = no data (value traps excluded)
Open-market buys & sells by this company's officers & directors (SEC Form 4)
Observational — buy/sell facts only, not a recommendation. Filing dates (the trade was 1–2 business days earlier). Routine comp (option exercises, grants) excluded — discretionary buys/sells only.
The chart (long-term trend, Ichimoku cloud) is for observation only — not a buy or sell signal.
A highlight of the key metrics detailed below.
Top-tier in 0 of 1 evaluated strategies
Ranks within the US market — tap to open that ranking (ranks are per market).
Past returns — they do not guarantee future results.
A Japanese trend tool. Price above the 'cloud' is supportive; below is weak. A strong uptrend doesn't mean it's cheap — stocks that have run up are usually more expensive.